Opportunity
SAM #NCI-SS-DCTD-BCBS-0001
NCI Cancer Biospecimen Collection and Biobanking Services
Buyer
NIH Office of Logistics and Acquisition Operations
Posted
November 20, 2026
Respond By
December 11, 2026
Identifier
NCI-SS-DCTD-BCBS-0001
NAICS
621991, 541380
NIH is conducting market research for NCI cancer biospecimen collection and biobanking services. - Government buyer: National Institutes of Health (NIH), Office of Acquisitions, for the National Cancer Institute (NCI), Division of Cancer Treatment and Diagnosis (DCTD); services may also support other NIH Institutes and Centers. - OEMs and vendors: No product manufacturers, prospective vendors, or resellers are identified. CAP/BAP and CLIA are accreditation and regulatory requirements, not vendors. - Requested services: - Identify, evaluate, onboard, train, and coordinate clinical sites in the United States and Canada; support study enrollment, site documentation and monitoring, collection-kit distribution, shipment tracking, and identification of existing biospecimen collections. - Operate a College of American Pathologists (CAP) Biorepository Accreditation Program (BAP)-accredited biorepository, including specimen receipt, processing, quality assessment, storage, tracking, inventory, and distribution; provide pathology and histology, training, quality assurance, and data-management and reporting capabilities, including an onsite board-certified anatomic pathologist. - Provide the above biorepository and pathology capabilities with additional CLIA accreditation and applicable New York State and California licenses for potential clinical testing. - Notable requirements: Support biospecimen and associated data collection, processing, storage, and distribution for current and future cancer research. No part numbers or fixed quantities are specified. - Anticipated performance: Five years total—one base year and four one-year option periods.
Description
TYPE OF NOTICE: This is a Sources Sought Notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The National Institutes of Health (NIH) Office of Acquisitions and Logistics Management, on behalf of the National Cancer Institute’s (NCI’s) Division of Cancer Treatment and Diagnosis (DCTD), is issuing this Sources Sought Notice to conduct market research and identify interested and capable parties, including both large and small businesses, that have the resources and expertise to support biospecimen collection, biobanking, and related services. The required services will support cancer research across the United States by providing specialized expertise to identify, establish, and manage clinical sites across the nation to engage and enroll cancer patients onto NCI biospecimen collection protocols, collect biospecimens and associated medical data, and to provide biorepository services. Research studies may include, but are not limited to, development of patient-derived animal models, tumor characterization, pharmacokinetic and pharmacodynamic studies, assay development and validation, clinical testing, and collection and management of biospecimens for future use. The Government intends to procure these specialized services through a competitive acquisition. BASED ON THE RESPONSES TO THIS SOURCES SOUGHT NOTICE (MARKET RESEARCH), all Small Business Set-Aside categories will be considered for this procurement. Telephone inquiries will not be accepted or acknowledged, and no feedback or evaluations will be provided to companies regarding their submissions.
PLACE OF PERFORMANCE: Performance of services for this effort will primarily take place at Contractor and/or Subcontractor facilities.
DISCLAIMER: THIS SOURCES SOUGHT IS FOR INFORMATIONAL PURPOSES ONLY. THIS IS NOT A “REQUEST FOR PROPOSAL (RFP)”. IT DOES NOT CONSTITUTE A SOLICITATION AND SHALL NOT BE CONSTRUED AS A COMMITMENT BY THE GOVERNMENT. RESPONSES IN ANY FORM ARE NOT OFFERS AND THE GOVERNMENT IS UNDER NO OBLIGATION TO AWARD A CONTRACT AS A RESULT OF THIS ANNOUNCEMENT. NO FUNDS ARE AVAILABLE TO PAY FOR PREPARATION OF RESPONSES TO THIS ANNOUNCEMENT. ANY INFORMATION SUBMITTED BY RESPONDENTS TO THIS NOTICE IS STRICTLY VOLUNTARY. RESPONSES WILL NOT BE RETURNED TO THE RESPONDER. NOT RESPONDING TO THIS NOTICE DOES NOT PRECLUDE PARTICIPATION IN ANY FUTURE REQUEST FOR QUOTE (RFQ), INVITATION FOR BID (IFB) OR RFP, IF ISSUED. IF A SOLICITATION IS RELEASED, IT WILL BE SYNOPSIZED ON THE GOVERNMENT-WIDE POINT OF ENTRY (GPE). IT IS THE RESPONSIBILITY OF POTENTIAL OFFERORS TO MONITOR THE GPE FOR ADDITIONAL INFORMATION PERTAINING TO THIS REQUIREMENT. THE GOVERNMENT RESERVES THE RIGHT TO USE INFORMATION PROVIDED BY RESPONDENTS FOR ANY PURPOSE DEEMED NECESSARY AND LEGALLY APPROPRIATE. ANY ORGANIZATION RESPONDING TO THIS NOTICE SHOULD ENSURE THAT ITS RESPONSE IS COMPLETE AND SUFFICIENTLY DETAILED TO ALLOW THE GOVERNMENT TO DETERMINE THE ORGANIZATION'S QUALIFICATIONS TO PERFORM THE WORK.
PROGRAM BACKGROUND: NCI uses research biospecimens including tissues, blood, and other bodily fluids donated by patients as part of scientific research to develop novel diagnostics and therapies for cancer. The Contractor shall be responsible for providing services to identify and engage clinical sites in conducting NCI biospecimen collection studies and to provide biorepository services for concurrent multi-disciplinary studies and diverse study designs. Biospecimens and associated data of known quality are a critical resource for research that investigates the causes, biology, diagnosis, prevention, and treatment of cancer. NCI requires biospecimens for research purposes that may include, but are not limited to, the following: development of patient-derived models, characterization of tumors using clinical- and research-grade sequencing, proteomics studies, pharmacodynamic studies, development and validation of clinical assays, performance of clinical testing and return of clinical test results to providers and patients, and development of research reserves of biospecimens for future research use.
REQUIRED CAPABILITIES: The objective of any potential contract is to obtain specialized services for the identification and coordination of clinical sites in the management of specific NCI biospecimen collection studies and the collection, processing, storage, and distribution of biospecimens and associated data for current and future cancer research. For specific details under each domain, please reference the draft Statement of Work which accompanies announcement. The Government encourages feedback from respondents in their capability submissions (i.e., comments, suggestions, recommendations) on the draft Statement of Work that would improve the understanding of the requirements for this anticipated acquisition. NCI is seeking the following information from respondents regarding strategies as well as explicit examples of how they would propose to support NCI initiatives in one or more of the following services areas:
DOMAIN 1: CLINICAL SITE IDENTIFICATION AND ONBOARDING, CLINICAL SITE MANAGEMENT, TRAINING, PROVISION OF KITS, AND IDENTIFICATION OF EXISTING BIOSPECIMEN COLLECTIONS Domain 1 describes the biospecimen collection activities needed to identify and manage medical institutions (herein referred to as Clinical Sites) across the United States and Canada to engage and enroll cancer patients onto specific NCI biospecimen collection studies and to provide biospecimen collection kit services for the studies. NCI biospecimen collection studies will include collection of biospecimens and associated medical data. Some studies will require the identification of existing cancer biospecimen collections that meet quality and quantity metrics prescribed by the NCI and that are appropriately consented for use by NCI. The Contractor shall ensure these activities are conducted safely, efficiently, and in compliance with regulatory requirements as specified in IRB-approved NCI studies.
DOMAIN 2: COMPREHENSIVE BIOREPOSITORY SERVICES, ACCREDITATION BY THE COLLEGE OF AMERICAN PATHOLOGISTS’ BIOREPOSITORY ACCREDITATION PROGRAM (CAP/BAP), PATHOLOGY AND HISTOLOGY, TRAINING, QUALITY ASSURANCE, AND INFORMATION TECHNOLOGY. Domain 2 describes comprehensive biorepository services performed under biorepository accreditation by the College of American Pathologists’ Biorepository Accreditation Program (CAP/BAP) and employing an onsite board-certified anatomic pathologist. Ability to provide expertise in tracking of pre-analytical variables and detailed inventory management for all biorepository activities per CAP/BAP requirements using an existing data management solution. Information technology support dedicated to biobanking operations, to include data and information collection, management, quality control and analysis. Ability to provide scientific expertise and leadership in biobanking activities including but not limited to appropriate processing of biospecimens into molecular analytes and appropriate biospecimen and analyte storage. Ability to provide administrative, program, and project support by performing administrative duties to provide continuity for office operations and procedures.
DOMAIN 3: COMPREHENSIVE BIOREPOSITORY SERVICES, ACCREDITATION BY THE COLLEGE OF AMERICAN PATHOLOGISTS’ BIOREPOSITORY ACCREDITATION PROGRAM (CAP/BAP), CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988 (CLIA) AND PATHOLOGY SUPPORT Domain 3 describes comprehensive biorepository services with ability to provide services as described in Domain 2. This work should be performed under biorepository accreditation by the College of American Pathologists’ Biorepository Accreditation Program (CAP/BAP) and employing an onsite board-certified anatomic pathologist, with additional requirements related to the potential return of results to research participants: performance under the Clinical Laboratory Improvement Amendment (CLIA) accreditation and additional licensing requirements of New York State and California. The contractor shall possess or shall be in the process of obtaining CLIA accreditation and the license and capabilities to conduct requirements in New York State and California.
The Government will evaluate the market research information received to ascertain potential market capacity to: Provide services consistent in scope and scale with those described in this notice and otherwise anticipated. Secure and apply the full range of corporate financial, human capital, and technical resources required to successfully perform similar requirements. Implement a successful project management plan that includes compliance with tight program schedules, cost containment, event and tracking performance, hiring and retention of key personnel and risk mitigation. Provide specialized support services under a service contract.
ELIGIBILITY: The anticipated primary NAICS code for this requirement is 541380, “Testing Laboratory and Services,” with a Small Business Size Standard of $19M. NAICS code 621511, “Medical Laboratories,” with a Small Business Size Standard of $41.5M, is under consideration. The Product Service Code applicable to this effort and Domains 1 through 3 are: Q301 – Laboratory Testing Services (preponderance of services)
ADDITIONAL INFORMATION AND SUBMISSION DETAILS: Interested parties shall submit a capabilities statement of no more than ten pages in length in Times New Roman font, 10pt or larger. Your submission shall be electronically submitted to the Contracting Officer, Eve Van Buren, at eve.vanburen@nih.gov in Portable Document Format (PDF) not later than 3:00 p.m. Eastern Time on December 11, 2026. All responses must be received by the specified due date and time in order to be considered. Capability statements received after that date and time will not be considered. No phone calls will be accepted. Submissions, at a minimum, shall include the following information: What type of work has your company performed in the past in support of the same or similar requirements? Can or has your company managed tasks of this nature? If so, provide details. Provide details of existing or past partnerships and established relationships with clinical sites, if applicable. Has your company managed a team of subcontractors before? If so, provide details. What specific technical skills does your company possess which ensure capability to perform the tasks? Provide a statement including your current business size status, company name and address, CAGE, Tax Identification numbers and company profile to include number of employees, annual revenue history, office locations, and Unique Entity Identification (UEI) number. Respondents to this notice also must indicate whether they qualify as a Small, Small Disadvantaged, Women-Owned, HUBZone, or Service-Disabled Veteran-Owned Small Business Concern. Include in your response your ability, if applicable, to meet the CLIA requirements under Service Area C. Provide any additional information that you believe we should know about your company in support of your submission. Identify whether commercial products, platforms, or services could meet all or a substantial portion of this requirement. If so, describe what portion could be met commercially and what portion would require customization, integration, or custom development. Identify whether any portion of this requirement could be accomplished under a firm-fixed-price contract. If a firm-fixed-price contract is not feasible, identify the proposed contract type. Identify any existing contract vehicles (e.g., GSA Schedules, other Government Wide Acquisition Contracts (GWACs)) that industry recommends for fulfilling this requirement. The anticipated period of performance, inclusive of options, for this proposed acquisition is five years with a one-year base period and four one-year option periods. The Government anticipates making multiple awards issued as Indefinite Delivery Indefinite Quantity contracts, depending on the final acquisition strategy. After evaluation of capability statements, if it is determined this requirement will be an unrestricted competition, the Government intends to evaluate the responses from small businesses and conduct further market research to identify a subcontracting goal. All data received in response to this notice that is marked or designated as corporate or proprietary will be fully protected from release outside the Government. All questions must be submitted to the Contracting Officer identified above. The Government is not obligated to pay for the information provided, and no basis for claims against the Government shall arise from a response to this notice. Respondents to this notice may be requested to provide an on-site briefing to NCI staff to further define capabilities.
CONFIDENTIALITY: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitations.